Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Aug 8;16:3329–3339. doi: 10.2147/JIR.S418276

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 Zhai et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Development and validation of the nomogram. (A) The nomogram for predicting pCR for NSCLC patients after neoadjuvant immunochemotherapy, according to which, each variable could be assigned a score on the point scale, by adding up the total score and locating it on the total point scale, we could draw a straight line down to determine the estimated probability of pCR; (B) the receiver operating characteristic curve for the nomogram; (C) the calibration plots for the nomogram. Predicted and actual pCR probability were respectively plotted on the X-axis and the Y-axis. The 45-degree dashed lines through the coordinate origin represent the excellent calibration models; (D) the decision curve analysis of the clinical value for the nomogram indicated that when the nomogram is used to predict the risk (probability) of pCR, patients could obtain better clinical benefits within wide range of risk (probability) threshold. The gray curve represents the hypothesis that all patients with NSCLC undergoing neoadjuvant immunochemotherapy. The black line represents the hypothesis that all NSCLC patients do not undergo neoadjuvant immunochemotherapy.